SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Naoto Sassa, Katsuhiko Kato, Shinji Abe, Shingo Iwano, Shinji Ito, Mitsuru Ikeda, Kazuhiro Shimamoto, Seiichi Yamamoto, Tokunori Yamamoto, Momokazu Gotoh, Shinji Naganawa, Evaluation of 11C-choline PET/CT for primary diagnosis and staging of urothelial carcinoma of the upper urinary tract: a pilot study, European Journal of Nuclear Medicine and Molecular Imaging, 2014,

    CrossRef

  2. 2
    Hussein M. Khaled, Hanan E. Shafik, M.S. Zabhloul, M. Ghoneim, R.A. Saber, M. Manie, H.A. Enein, H.A. Megeed, O. Mansur, M.E. Sherbini, T.Z. Mahran, M.E. Kalawee, A. Badran, Safaa M. Ramadan, Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Invasive Transitional and Squamous Cell Carcinoma of the Bladder: Effect on Survival and Bladder Preservation, Clinical Genitourinary Cancer, 2014, 12, 5, e233

    CrossRef

  3. 3
    Jong Chul Park, Deborah E. Citrin, Piyush K. Agarwal, Andrea B. Apolo, Multimodal management of muscle-invasive bladder cancer, Current Problems in Cancer, 2014, 38, 3, 80

    CrossRef

  4. 4
    Francesc Pons, Joaquim Bellmunt, Sunitinib malate in the treatment of urothelial cancer, Expert Opinion on Investigational Drugs, 2014, 23, 1, 115

    CrossRef

  5. 5
    Petros D. Grivas, Maha Hussain, Khaled Hafez, Stephanie Daignault-Newton, David Wood, Cheryl T. Lee, Alon Weizer, James E. Montie, Brent Hollenbeck, Jeffrey S. Montgomery, Ajjai Alva, David C. Smith, A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder, Urology, 2013, 82, 1, 111

    CrossRef

  6. 6
    Nobuaki Matsubara, Hirofumi Mukai, Yoichi Naito, Masahiko Nezu, Kuniaki Itoh, Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer, Asia-Pacific Journal of Clinical Oncology, 2013, 9, 4
  7. 7
    Takuya Koie, Chikara Ohyama, Yasuhiro Hashimoto, Shingo Hatakeyama, Hayato Yamamoto, Takahiro Yoneyama, Noritaka Kamimura, Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study, International Journal of Clinical Oncology, 2013, 18, 4, 724

    CrossRef

  8. 8
    Itay A. Sternberg, Guido Dalbagni, Ling Y. Chen, Sherri M. Donat, Bernard H. Bochner, Harry W. Herr, Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guérin Treatment Failure, The Journal of Urology, 2013, 190, 5, 1686

    CrossRef

  9. 9
    Damien Pouessel, Pierre Mongiat-Artus, Stéphane Culine, Neoadjuvant chemotherapy in muscle-invasive bladder cancer: Ready for prime time?, Critical Reviews in Oncology/Hematology, 2013, 85, 3, 288

    CrossRef

  10. 10
    Günter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian D. Stensland, Peter Albers, Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?, European Urology, 2013, 64, 3, 355

    CrossRef

  11. 11
    Adrian S. Fairey, Siamak Daneshmand, David Quinn, Tanya Dorff, Ryan Dorin, Gary Lieskovsky, Anne Schuckman, Jie Cai, Gus Miranda, Eila C. Skinner, Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California, Urologic Oncology: Seminars and Original Investigations, 2013, 31, 8, 1737

    CrossRef

  12. 12
    K. Iwasaki, W. Obara, Y. Kato, R. Takata, S. Tanji, T. Fujioka, Neoadjuvant Gemcitabine Plus Carboplatin for Locally Advanced Bladder Cancer, Japanese Journal of Clinical Oncology, 2013, 43, 2, 193

    CrossRef

  13. 13
    Bertram E. Yuh, Nora Ruel, Timothy G. Wilson, Nicholas Vogelzang, Sumanta K. Pal, Pooled Analysis of Clinical Outcomes with Neoadjuvant Cisplatin and Gemcitabine Chemotherapy for Muscle Invasive Bladder Cancer, The Journal of Urology, 2013, 189, 5, 1682

    CrossRef

  14. 14
    Bastian Keck, Sven Wach, Peter J. Goebell, Frank Kunath, Simone Bertz, Jan Lehmann, Michael Stöckle, Helge Taubert, Bernd Wullich, Arndt Hartmann, SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer, Annals of Surgical Oncology, 2013, 20, 11, 3669

    CrossRef

  15. 15
    Shabnam Rehman, Alice Crane, Rakeeba Din, Syed Johar Raza, Yi Shi, Gregory Wilding, Ellis G. Levine, Saby George, Roberto Pili, Donald L. Trump, Khurshid A. Guru, Understanding Avoidance, Refusal, and Abandonment of Chemotherapy Before and After Cystectomy for Bladder Cancer, Urology, 2013, 82, 6, 1370

    CrossRef

  16. You have free access to this content16
    Mun Sem Liew, Arun Azad, Ali Tafreshi, Renu Eapen, Damien Bolton, Ian D. Davis, Shomik Sengupta, USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer, BJU International, 2013, 112,
  17. 17
    Robert Rosenblatt, Amir Sherif, Erkki Rintala, Rolf Wahlqvist, Anders Ullén, Sten Nilsson, Per-Uno Malmström, Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer, European Urology, 2012, 61, 6, 1229

    CrossRef

  18. 18
    Guru Sonpavde, Shahrokh F. Shariat, Preoperative chemotherapy for bladder cancer, Cancer, 2012, 118, 1
  19. 19
    Sumanta K. Pal, Nora H. Ruel, Timothy G. Wilson, Bertram E. Yuh, Retrospective Analysis of Clinical Outcomes With Neoadjuvant Cisplatin-Based Regimens for Muscle-Invasive Bladder Cancer, Clinical Genitourinary Cancer, 2012, 10, 4, 246

    CrossRef